SEC filing record
Primary Source · SEC.gov

Patient Square Premium Coinvest, L.P.

Co-Investment Vehicle2026 vintage506(b), 3(c)(1)
Latest signalNew Form D filerForm D · 2025-11-14Last filing 2025-11-14

Raised

$50M

Investors

10

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

AltStreet Analysis

·

Generated from EDGAR primary sources

Patient Square Premium Coinvest, L.P. is a Delaware-organized co-investment fund vehicle that filed an amended Form D on 2026-11-16, reporting $50.0M raised from 10 investors under the Rule 506(b) exemption combined with the Section 3(c)(1) investment company exclusion. Related persons James Momtazee and Adam Fliss are listed as executive officers and promoters, consistent with Patient Square Capital's healthcare-focused investment platform; minimum investment and first sale date are not disclosed on the filing.

This is a private co-investment vehicle typical of healthcare/PE sponsor platforms, pairing a 506(b) private placement exemption with a 3(c)(1) fund exclusion — a standard structure for funds limited to 100 or fewer beneficial owners. The $50.0M raise across 10 investors implies an average commitment of roughly $5.0M, consistent with institutional/accredited-investor co-invest vehicles rather than retail-oriented offerings; no minimum investment figure is stated on the filing itself.

Data Flags

ExemptionFiling claims both Rule 506(b) and Section 3(c)(1) simultaneously — a standard combination for private pooled investment funds restricting beneficial owners, not indicative of an irregularity.
First Sale DateFirst sale date is not disclosed despite the filing reporting $50.0M already raised from 10 investors; since total raise is under the $100M threshold where this omission is typically expected for large institutional amendments, this is worth noting.
Industry GroupIndustry group field is not specified on the filing.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002095564
Entity NamePatient Square Premium Coinvest, L.P.
ExemptionRule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company. Section 3(c)(1) of the Investment Company Act: the fund is excluded from investment-company registration because it has no more than 100 beneficial owners. Section 3(c)(7) of the Investment Company Act: the fund is excluded from investment-company registration because every investor is a qualified purchaser, generally an individual with at least $5 million in investments or an institution with at least $25 million.
Entity TypeLimited Partnership
Jurisdiction of OrganizationDelaware
Issuer Address2884 Sand Hill Road, Suite 100, Menlo Park, CA 94025
Phone(650) 677-8100
Industry / Fund TypePooled Investment Fund · Private Equity Fund
Investment Company ActExcluded under Section 3(c)(1) (100 beneficial owners or fewer) and Section 3(c)(7) (qualified purchasers only) (both boxes checked on the filing)
Securities TypeEquity, Pooled Investment Fund
First Sale DateNot yet occurred (as filed)
Filing DateNovember 16, 2026
Accession Number0002095564-26-000001
Total Offering AmountIndefinite
Total Amount Sold$50,000,000
Total Investors10
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$0
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)CA
Amendment CountOriginal filing only

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Nov 14, 2025

Critical / warning

0 / 0

0 watch · 1 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

pre_sale

Latest event New filer · Nov 14, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 1 filing event with values and deltas, latest 2025-11-14, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

James Momtazee

Executive Officer, Promoter · Menlo Park, CA

Adam Fliss

Executive Officer, Promoter · Menlo Park, CA

Questions About Patient Square Premium Coinvest, L.P.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Patient Square Premium Coinvest, L.P.?

Patient Square Premium Coinvest, L.P. is a Delaware limited partnership that filed a Form D with the SEC on November 14, 2025 as a private equity fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7) for an offering of equity and pooled investment fund interests.

Is Patient Square Premium Coinvest, L.P. legit?

AltStreet does not rate legitimacy; it reports the public record. Patient Square Premium Coinvest, L.P. filed a Form D with the SEC on November 14, 2025 claiming Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Patient Square Premium Coinvest, L.P. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Patient Square Premium Coinvest, L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Patient Square Premium Coinvest, L.P. raised?

Patient Square Premium Coinvest, L.P. reported that the first sale had not yet occurred as of the Form D filed November 14, 2025, so no amount sold or investor count is on file. The total offering amount is listed as indefinite.

Who can invest in Patient Square Premium Coinvest, L.P.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing checks both Section 3(c)(1), which caps the fund at 100 beneficial owners, and Section 3(c)(7), which requires every investor to be a qualified purchaser, generally an individual with at least $5 million in investments. A fund normally relies on one or the other. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Patient Square Premium Coinvest, L.P.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Patient Square Premium Coinvest, L.P. and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Patient Square Premium Coinvest, L.P.?

The Form D lists 2 related persons: James Momtazee, executive officer, promoter; Adam Fliss, executive officer, promoter. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Patient Square Premium Coinvest, L.P. located?

The issuer's address on its SEC filings is 2884 Sand Hill Road, Suite 100, Menlo Park, CA 94025. Its phone number of record is (650) 677-8100. It is organized under the laws of Delaware.

How long is the Patient Square Premium Coinvest, L.P. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

How large is Patient Square Premium Coinvest, L.P.?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.